1. Variability in the reported management of pulmonary metastases in osteosarcoma.
- Author
-
Bhattasali O, Vo AT, Roth M, Geller D, Randall RL, Gorlick R, and Gill J
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant statistics & numerical data, Health Knowledge, Attitudes, Practice, Humans, Lung Neoplasms drug therapy, Lung Neoplasms surgery, Medicine statistics & numerical data, Neoadjuvant Therapy statistics & numerical data, Osteosarcoma drug therapy, Osteosarcoma surgery, Retrospective Studies, Thoracotomy statistics & numerical data, Bone Neoplasms, Lung Neoplasms secondary, Osteosarcoma secondary, Practice Patterns, Physicians' statistics & numerical data
- Abstract
Nearly 20% of patients with newly diagnosed osteosarcoma have detectable metastases at diagnosis; the majority of which occur in the lungs. There are no established recommendations for the timing and modality of metastasectomy. Members of the Connective Tissue Oncology Society (CTOS) were emailed an anonymous 10-min survey assessing their management practices for pulmonary findings at the time of an osteosarcoma diagnosis. The questionnaire presented three scenarios and discussed the choice to perform surgery, the timing of resection, and the choice of surgical procedure. Analyses were stratified by medical profession. One hundred and eighty-three physicians responded to our questionnaire. Respondents were comprised of orthopedic surgeons (37%), medical oncologists (31%), pediatric oncologists (22%), and other medical subspecialties (10%). There was variability among the respondents in the management of the pulmonary nodules. The majority of physicians chose to resect the pulmonary nodules following neoadjuvant chemotherapy (46-63%). Thoracotomy was the preferred technique for surgical resection. When only unilateral findings were present, the majority of physicians did not explore the contralateral lung. The majority of respondents did not recommend resection if the pulmonary nodule disappeared following chemotherapy. The survey demonstrated heterogeneity in the management of pulmonary metastases in osteosarcoma. Prospective trials need to evaluate whether these differences in management have implications for outcomes for patients with metastatic osteosarcoma., (© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF